NGEN NERVGEN PHARMA CORP. IFRS Annual reports only
Pharmaceutical Preparations · Nasdaq · SEC CIK 1751912 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY2025*2025-12-31 | FY2024*2024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | 13.91M | 15.81M |
| SG&A expense | 11.17M | 9.37M |
| Net income | -44.12M | -24.25M |
| EPS (basic) | -0.61 | -0.36 |
| EPS (diluted) | -0.61 | -0.36 |
| Weighted avg. shares (diluted) | 72.33M | 67.32M |
| Balance sheet | ||
| Cash & equivalents | 22.07M | 17.27M |
| Receivables | 80,825 | 415,301 |
| Current assets | 22.80M | 19.01M |
| Intangibles | 409,163 | 464,958 |
| Total assets | 23.21M | 19.49M |
| Current liabilities | 19.73M | 16.90M |
| Total liabilities | 19.73M | 16.91M |
| Shareholders' equity | 3.48M | 2.58M |
| Shares outstanding | 79.65M | 70.33M |
| Cash flow statement | ||
| Operating cash flow | -19.50M | -16.84M |
| Investing cash flow | 100,926 | 58,874 |
| Financing cash flow | 23.76M | 22.70M |
| Stock-based compensation | 5.39M | 6.04M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.